Literature DB >> 15078168

Chemistry of cyclic ADP-ribose and its analogs.

Satoshi Shuto1, Akira Matsuda.   

Abstract

Cyclic ADP-ribose (cADPR), a general mediator involved in Ca2+ signaling, has the characteristic 18-membered ring consisting of an adenine, two riboses and a pyrophosphate, in which the two primary hydroxyl groups of the riboses are linked by a pyrophosphate unit. This review focuses on the chemical synthetic studies of cADPR analogs. These analogs have been used quite effectively in proving the mechanism of cADPR-mediated Ca2+ signaling pathways. These analogs are also expected to be lead structures for the development of drugs. Although cADPR analogs can be synthesized by enzymatic and chemo-enzymatic methods using ADP-ribosyl cyclase, the analogs obtained by these methods are limited due to the substrate-specificity of the enzymes. Consequently, chemical synthetic methods providing a greater variety of cADPR analogs are required. Chemical synthetic studies have demonstrated that the construction of the large 18-membered ring structure is quite difficult. Another problem encountered in the synthesis is the construction of the N1-substituted purine nucleoside structure. The N1-substituted inosine derivatives were prepared by condensation between the N1-(2,4-dinitrophenyl)inosine derivatives and the appropriate amines. For the preparation of the N1-substituted adenosine structures, condensation of the 4-cyano-5-(alkoxymethyleneamino)imidazole nucleosides with the appropriate amines was found to be effective. The first chemical construction of the 18-membered ring was achieved using a bisphosphate-type substrate conformationally restricted in the cyclized product-like syn-form around the N9-glycosyl linkage; however, the yield was inadequate. The key 18-membereding construction was significantly improved by employing the phenylthiophosphate-type substrates. When the substrates were activated by AgNO3 or I2 in the presence of molecular sieves in pyridine, the corresponding 18-membered ring products were obtained in high yields. Using this method as the key step, the chemically and biologically stable cADPR mimic, cADP-carbocyclic-ribose (cADPcR), was synthesized. This method has been applied subsequently to the synthesis of various cADPR analogs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078168     DOI: 10.2174/0929867043455639

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  12 in total

1.  Cellular effects and metabolic stability of N1-cyclic inosine diphosphoribose and its derivatives.

Authors:  T Kirchberger; G Wagner; J Xu; C Cordiglieri; P Wang; A Gasser; R Fliegert; S Bruhn; A Flügel; F E Lund; L-H Zhang; B V L Potter; A H Guse
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

2.  Design, Synthesis, and Chemical and Biological Properties of Cyclic ADP-4-Thioribose as a Stable Equivalent of Cyclic ADP-Ribose.

Authors:  Takayoshi Tsuzuki; Satoshi Takano; Natsumi Sakaguchi; Takashi Kudoh; Takashi Murayama; Takashi Sakurai; Minako Hashii; Haruhiro Higashida; Karin Weber; Andreas H Guse; Tomoshi Kameda; Takatsugu Hirokawa; Yasuhiro Kumaki; Mitsuhiro Arisawa; Barry V L Potter; Satoshi Shuto
Journal:  Messenger (Los Angel)       Date:  2014-06-01

3.  Synthesis of cyclic adenosine 5'-diphosphate ribose analogues: a C2'endo/syn "southern" ribose conformation underlies activity at the sea urchin cADPR receptor.

Authors:  Christelle Moreau; Gloria A Ashamu; Victoria C Bailey; Antony Galione; Andreas H Guse; Barry V L Potter
Journal:  Org Biomol Chem       Date:  2010-10-25       Impact factor: 3.876

4.  A novel fluorescent cell membrane-permeable caged cyclic ADP-ribose analogue.

Authors:  Pei-Lin Yu; Zhe-Hao Zhang; Bai-Xia Hao; Yong-Juan Zhao; Li-He Zhang; Hon-Cheung Lee; Liangren Zhang; Jianbo Yue
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

5.  Molecular bases of catalysis and ADP-ribose preference of human Mn2+-dependent ADP-ribose/CDP-alcohol diphosphatase and conversion by mutagenesis to a preferential cyclic ADP-ribose phosphohydrolase.

Authors:  Alicia Cabezas; João Meireles Ribeiro; Joaquim Rui Rodrigues; Iralis López-Villamizar; Ascensión Fernández; José Canales; Rosa María Pinto; María Jesús Costas; José Carlos Cameselle
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

6.  Synthesis of cyclic N (1)-pentylinosine phosphate, a new structurally reduced cADPR analogue with calcium-mobilizing activity on PC12 cells.

Authors:  Ahmed Mahal; Stefano D'Errico; Nicola Borbone; Brunella Pinto; Agnese Secondo; Valeria Costantino; Valentina Tedeschi; Giorgia Oliviero; Vincenzo Piccialli; Gennaro Piccialli
Journal:  Beilstein J Org Chem       Date:  2015-12-22       Impact factor: 2.883

7.  Synthesis and Biological Evaluation of a New Structural Simplified Analogue of cADPR, a Calcium-Mobilizing Secondary Messenger Firstly Isolated from Sea Urchin Eggs.

Authors:  Stefano D'Errico; Nicola Borbone; Bruno Catalanotti; Agnese Secondo; Tiziana Petrozziello; Ilaria Piccialli; Anna Pannaccione; Valeria Costantino; Luciano Mayol; Gennaro Piccialli; Giorgia Oliviero
Journal:  Mar Drugs       Date:  2018-03-10       Impact factor: 5.118

8.  Synthesis and calcium mobilization activity of cADPR analogues which integrate nucleobase, northern and southern ribose modifications.

Authors:  Yue Zhou; Peilin Yu; Hongwei Jin; Zhenjun Yang; Jianbo Yue; Liangren Zhang; Lihe Zhang
Journal:  Molecules       Date:  2012-04-10       Impact factor: 4.411

9.  Concise syntheses of trifluoromethylated cyclic and acyclic analogues of cADPR.

Authors:  Xiangchen Huang; Min Dong; Jian Liu; Kehui Zhang; Zhenjun Yang; Liangren Zhang; Lihe Zhang
Journal:  Molecules       Date:  2010-11-30       Impact factor: 4.411

10.  CD38 Structure-Based Inhibitor Design Using the N1-Cyclic Inosine 5'-Diphosphate Ribose Template.

Authors:  Christelle Moreau; Qun Liu; Richard Graeff; Gerd K Wagner; Mark P Thomas; Joanna M Swarbrick; Satoshi Shuto; Hon Cheung Lee; Quan Hao; Barry V L Potter
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.